Q2 2025 AtriCure Inc Earnings Call Transcript
Key Points
- AtriCure Inc (ATRC) reported a 17% year-over-year increase in total revenue, reaching $136 million for the second quarter of 2025.
- The company achieved over $15 million in adjusted EBITDA and nearly $18 million in cash generation during the quarter.
- New product launches, such as AtriClip, FLEX-Mini, and cryoSPHERE MAX, drove accelerated growth in pain management and appendage management.
- The completion of enrollment in the LeAAPS clinical trial marks a significant milestone, with over 6,500 patients enrolled, potentially expanding the standard of care in cardiac surgery.
- International revenue grew by 23.3% on a reported basis, with strong performance across European and Asia Pacific markets.
- Gross margin decreased by approximately 15 basis points compared to the second quarter of 2024, primarily due to less favorable geographic and product mix.
- The minimally invasive ablation sales faced pressure, ending the quarter at $7.8 million due to increased adoption of PFA catheter technology.
- Operating expenses increased by 14.5% from the previous year, driven by a $5 million milestone payment and increased R&D expenses.
- The company anticipates continued modest sequential declines in its US hybrid franchise for the remainder of 2025.
- Despite strong overall performance, the company expects typical summer seasonality to result in a low single-digit sequential decline in revenue from the second to third quarter.
Good afternoon and welcome to AtriCure's second quarter 2025 earnings conference call. This call is being recorded for replay purposes. (Operator Instructions)
I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments.
Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call 513-644-4484 to have one e-mail to you. Before we begin today, let me remind you that the company's remarks include forward-looking statements.
Forward-looking statements are subject to numerous risks and uncertainties many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings.
These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure franchises and growth initiatives, future product approvals and clearances, competition,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
